Pasar al contenido principal

AGREGACION DE PROTEINAS: IMPLEMENTACION DE NUEVAS ESTRATEGIAS BIOMEDICAS, ESTRUCTURALES Y NANOTECNOLOGICAS

PID2022-137963OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioengineered self-assembled nanofibrils for high-affinity SARS-CoV-2 capture and neutralization

  • Behbahanipour, Molood|||0000-0002-7889-6105
  • Navarro, Susanna|||0000-0001-8160-9536
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Ventura, Salvador|||0000-0002-9652-6351
The recent coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spurred intense research efforts to develop new materials with antiviral activity. In this study, we genetically engineered amyloid-based nanofibrils for capturing and neutralizing SARS-CoV-2. Building upon the amyloid properties of a short Sup35 yeast prion sequence, we fused it to SARS-CoV-2 receptor-binding domain (RBD) capturing proteins, LCB1 and LCB3. By tuning the reaction conditions, we achieved the spontaneous self-assembly of the Sup35-LCB1 fusion protein into a highly homogeneous and well-dispersed amyloid-like fibrillar material. These nanofibrils exhibited high affinity for the SARS-CoV-2 RBD, effectively inhibiting its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, the primary entry point for the virus into host cells. We further demonstrate that this functional nanomaterial entraps and neutralizes SARS-CoV-2 virus-like particles (VLPs), with a potency comparable to that of therapeutic antibodies. As a proof of concept, we successfully fabricated patterned surfaces that selectively capture SARS-CoV-2 RBD protein on wet environments. Collectively, these findings suggest that these protein-only nanofibrils hold promise as disinfecting coatings endowed with selective SARS-CoV-2 neutralizing properties to combat viral spread or in the development of sensitive viral sampling and diagnostic tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aggrescan4D, A comprehensive tool for pH-dependent analysis and engineering of protein aggregation propensity

  • Zalewski, Mateusz|||0000-0002-3436-8829
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
  • Kmiecik, Sebastian|||0000-0001-7623-0935
Aggrescan4D (A4D) is an advanced computational tool designed for predicting protein aggregation, leveraging structural information and the influence of pH. Building upon its predecessor, Aggrescan3D (A3D), A4D has undergone numerous enhancements aimed at assisting the improvement of protein solubility. This manuscript reviews A4D's updated functionalities and explains the fundamental principles behind its pH-dependent calculations. Additionally, it presents an antibody case study to evaluate its performance in comparison with other structure-based predictors. Notably, A4D integrates advanced protein engineering protocols with pH-dependent calculations, enhancing its utility in advising solubility-enhancing mutations. A4D considers the impact of structural flexibility on aggregation propensities, and includes a large set of precalculated predictions. These capabilities should help to open new avenues for both understanding and managing protein aggregation. A4D is accessible through a dedicated web server at https://biocomp.chem.uw.edu.pl/a4d/.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protein Nanoparticles for Targeted SARS-CoV-2 Trapping and Neutralization

  • Fornt Suñé, Marc|||0000-0003-1197-2836
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Ventura, Salvador|||0000-0002-9652-6351
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge global health despite widespread vaccination efforts, underscoring the need for innovative strategies to combat emerging infectious diseases effectively. Herein, LCB1-NPs and LCB3-NPs are engineered as a novel class of protein-only nanoparticles formed through coiled coil-driven self-assembly and tailored to interact specifically with the SARS-CoV-2 spike protein. The multivalency of LCB1-NPs and LCB3-NPs offers a strategy for efficiently targeting and neutralizing SARS-CoV-2 both in solution and when immobilized on surfaces. It is demonstrated that LCB1-NPs and LCB3-NPs bind to the SARS-CoV-2 spike protein's receptor-binding domain (RBD) with high affinity, effectively blocking the entry of SARS-CoV-2 virus-like particles into angiotensin-converting enzyme 2 (ACE2)-coated human cells. The cost-effectiveness, scalability, and straightforward production process of these protein nanoparticles make them suitable for developing novel anti-viral materials. Accordingly, it is shown how these nanostructures can be packed into columns to build up economic and highly potent trapping devices for SARS-CoV-2 adsorption.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aggregating amyloid resources, A comprehensive review of databases on amyloid-like aggregation

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Chilimoniuk, Jaroslaw|||0000-0001-5467-018X
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
  • Burdukiewicz, Michał|||0000-0001-8926-582X
Protein aggregation is responsible for several degenerative conditions in humans, and it is also a bottleneck in industrial protein production and storage of biotherapeutics. Bioinformatics tools have been developed to predict and redesign protein solubility more efficiently by understanding the underlying principles behind aggregation. As more experimental data become available, dedicated resources for storing, indexing, classifying and consolidating experimental results have emerged. These resources vary in focus, including aggregation-prone regions, 3D patches or protein stretches capable of forming amyloid fibrils. Some of these resources also consider the experimental conditions that cause protein aggregation and how they affect the process. This review article explores how protein aggregation databases have evolved and surveys state-of-the-art resources. We highlight their applications, complementarity and existing limitations. Moreover, we showcase the existing symbiosis between amyloid-related databases and predictive tools. To increase the usefulness of our review, we supplement it with a comprehensive list of present and past amyloid databases: https://biogenies.info/amyloid-database-list/.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of amphipathic and cationic helical peptides in Parkinson's disease

  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Ventura, Salvador|||0000-0002-9652-6351
Peptides are attracting a growing interest for therapeutic applications in biomedicine. In Parkinson's disease (PD), different human endogenous peptides have been associated with beneficial effects, including protein aggregation inhibition, reduced inflammation, or the protection of dopaminergic neurons. Such effects seem to be connected to the spatial arrangement of peptide side chains, and many of these human molecules share common conformational traits, displaying a distinctive amphipathic and cationic helical structure, which is believed to be crucial for their activities. This review delves into the relationship between these structural properties and the current evidence connecting biogenic peptides to the amelioration of PD symptoms. We discuss their implications in the disease, the different mechanisms of action, their state of validation, and their therapeutic potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The small molecule -2 inhibits the aggregation and seeded polymerisation of C-terminally truncated α-Synuclein

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation, particularly the formation of amyloid fibrils, is associated with numerous human disorders, including Parkinson's disease. This neurodegenerative condition is characterised by the accumulation of α-Synuclein amyloid fibrils within intraneuronal deposits known as Lewy bodies or neurites. C-terminally truncated forms of α-Synuclein are frequently observed in these inclusions in the brains of patients, and their increased aggregation propensity suggests a role in the disease's pathogenesis. This study demonstrates that the small molecule ZPD-2 acts as a potent inhibitor of both the spontaneous and seeded amyloid polimerisation of C-terminally truncated α-Synuclein by interfering with early aggregation intermediates. This dual activity positions this molecule as a promising candidate for therapeutic development in treating synucleinopathies. The aggregation of α-Synuclein plays a key role in Parkinson's disease. Remarkably, the C-terminal region of this protein contributes to inhibit amyloid formation and its truncation enhances this process. In this work, we demonstrated that the addition of small molecules, ZPD-2 or SynuClean-D, inhibits the aggregation of C-terminally truncated α-Synuclein. Overall, the data suggested different inhibitory mechanisms with ZPD-2 outperforming SC-D by acting at the initial stages of aggregation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aggrescan4D, structure-informed analysis of pH-dependent protein aggregation

  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Kuriata, Aleksander
  • Zalewski, Mateusz|||0000-0002-3436-8829
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Firlik, Grzegorz
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Kmiecik, Sebastian|||0000-0001-7623-0935
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is behind the genesis of incurable diseases and imposes constraints on drug discovery and the industrial production and formulation of proteins. Over the years, we have been advancing the Aggresscan3D (A3D) method, aiming to deepen our comprehension of protein aggregation and assist the engineering of protein solubility. Since its inception, A3D has become one of the most popular structure-based aggregation predictors because of its performance, modular functionalities, RESTful service for extensive screenings, and intuitive user interface. Building on this foundation, we introduce Aggrescan4D (A4D), significantly extending A3D's functionality. A4D is aimed at predicting the pH-dependent aggregation of protein structures, and features an evolutionary-informed automatic mutation protocol to engineer protein solubility without compromising structure and stability. It also integrates precalculated results for the nearly 500,000 jobs in the A3D Model Organisms Database and structure retrieval from the AlphaFold database. Globally, A4D constitutes a comprehensive tool for understanding, predicting, and designing solutions for specific protein aggregation challenges. The A4D web server and extensive documentation are available at . This website is free and open to all users without a login requirement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson's disease model

  • Blasco-Agell, Lucas
  • Pons-Espinal, Meritxell
  • Testa, Veronica
  • Roch, Gerard|||0000-0002-9045-0579
  • Montero-Muñoz, Jara
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Baruffi, Valentina
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Richaud-Patin, Yvonne
  • Jimenez, Senda
  • Cuadros, Thais|||0000-0001-6994-2424
  • Cladera-Sastre, Joana Margalida
  • Compte, Joan|||0000-0001-5447-5122
  • Manglano-Artuñedo, Zoe
  • Ventura, Salvador|||0000-0002-9652-6351
  • Juan, Manel|||0000-0002-3064-1648
  • Tolosa, Eduardo
  • Raya, Ángel|||0000-0003-2189-9775
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Consiglio, Antonella
Parkinson's disease (PD) is a progressive, incurable neurodegenerative disorder characterized by the loss of neuromelanin (NM)-containing dopamine neurons (DAn) in the substantia nigra of the midbrain. Non-neuronal cells are increasingly recognized as contributors to PD. We generated human microglia-like cells (hMG) from induced pluripotent stem cells (iPSC) derived from patients with LRRK2 PD-causing mutations, gene-corrected isogenic controls, and healthy donors. While neither genotype induced neurodegeneration in healthy DAn, LRRK2 hMG become hyperreactive to LPS stimulation, exhibiting increased cytokine expression, reactive oxygen species, and phagocytosis. When exposed to NM-containing particles, but not α-synuclein fibrils, LRRK2 hMG trigger DAn degeneration, in a process that is prevented by pre-treatment with the immunomodulatory drug ivermectin. Finally, post-mortem analysis of midbrain tissue of LRRK2-PD patients show increased microglia activation around NM-containing neurons, confirming our in vitro findings. Overall, our work highlights NM-activated microglia's role in PD progression, and provides a model for testing therapeutic targets. (Figure presented.).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MIA40 circumvents the folding constraints imposed by TRIAP1 function

  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Fornt Suñé, Marc|||0000-0003-1197-2836
  • Gil-Garcia, Marcos|||0000-0002-7457-7860
  • Bartolomé-Nafría, Andrea|||0000-0003-3114-1415
  • Canals, Francesc|||0000-0002-0650-1135
  • Cerofolini, Linda
  • Teilum, Kaare
  • Banci, Lucia
  • Esperante, Sebastián|||0000-0002-5778-6871
  • Ventura, Salvador|||0000-0002-9652-6351
The MIA40 relay system mediates the import of small cysteine-rich proteins into the intermembrane mitochondrial space (IMS). MIA40 substrates are synthesized in the cytosol and assumed to be disordered in their reduced state in this compartment. As they cross the outer mitochondrial membrane, MIA40 promotes the oxidation of critical native disulfides to facilitate folding, trapping functional species in the IMS. Here, we study the redox-controled folding of TRIAP1, a small cysteine-rich protein with moonlighting function: regulating phospholipid trafficking between mitochondrial membranes in the IMS and preventing apoptosis in the cytosol. TRIAP1 dysregulation is connected to oncogenesis. Although TRIAP1 contains a canonical twin CX9C motif, its sequence characteristics and folding pathway deviate from typical MIA40 substrates. In its reduced state, TRIAP1 rapidly populates a hydrophobic collapsed, alpha-helical, and marginally stable molten globule. This intermediate biases oxidative folding towards a non-native Cys37-Cys47 kinetic trap, slowing the reaction. MIA40 accelerates TRIAP1 folding rate by 30-fold, bypassing the formation of this folding trap. MIA40 drives the oxidation of the inner disulfide bond Cys18-Cys37, and subsequently, it can catalyze the formation of the outer disulfide bond Cys8-Cys47 to attain the native two-disulfide-bridged structure. We demonstrate that, unlike most MIA40 substrates, TRIAP1's folding pathway is strongly constrained by the structural requirements for its function in phospholipid traffic at the IMS. The obligatory population of a reduced, alpha-helical, metastable molten globule in the cytoplasm may explain TRIAP1's connection to the p53-dependent cell survival pathway, constituting a remarkable example of a functional molten globule state.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multivalent Protein Nanorings for Broad and Potent SARS-CoV-2 Neutralization

  • Behbahanipour, Molood|||0000-0002-7889-6105
  • Goldin, Carla|||0000-0001-8996-4153
  • Prato, Cecilia Arahi
  • Paletta, Ana Luz|||0000-0003-2181-8488
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Navarro, Susanna|||0000-0001-8160-9536
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Murgida, Daniel H.
  • Tribulatti, María Virginia|||0000-0003-0507-065X
  • Esperante, Sebastián|||0000-0002-5778-6871
  • Alvarez-Paggi, Damian|||0000-0002-1507-9685
  • Ventura, Salvador|||0000-0002-9652-6351
The ongoing threat of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the limitations of conventional antibody-based therapeutics (ABTs) underscore the need for scalable and customizable antiviral platforms. A modular, protein-only nanoscaffold based on recombinant ring-like particles (RLPs) derived from a viral nucleoprotein (NP), engineered is presented to display high-affinity, de novo-designed minibinders (LCB1 and LCB3) targeting SARS-CoV-2 Spike (S)protein. These binders are site-specifically fused to either the N- or C-termini, or both ends of NP to ensure functional orientation and dense, multivalent display. The resulting constructs self-assemble into stable, biocompatible, and homogeneous nanoparticles that potently inhibit S-angiotensin-converting enzyme 2 receptor (ACE2r) interactions, neutralizing both pseudotyped viral-like particles and authentic SARS-CoV-2, including Omicron BA.5. The dual-display nanoparticle (RLP-1,3), presenting 10 LCB1 and 10 LCB3 domains, exhibit synergistic binding activity, with fM Half Maximal Inhibitory Concentration(IC) values, outperforming benchmark monoclonal antibodies and clinically approved hyperimmune therapies. Additionally, RLP-1,3 is adapted for diagnostics in an ELISA platform, achieving a Spike protein detection limit of 9 ng mL, surpassing commercial assays. This work demonstrates how the convergence of AI-guided binder design and structure-based nanoscaffolding enables next-generation multifunctional bio-nanomaterials. The RLP-minibinder system offers a generalizable, scalable, and cost-efficient plug-and-(dis)play solution with integrated therapeutic and diagnostic capabilities, positioning it as a flexible alternative to ABTs for pandemic preparedness.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations

  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Kant, Ravi|||0000-0002-0099-4346
  • Chemuru, Saketh
  • Varejão, Nathalia|||0000-0002-6952-8896
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Gross, Michael L.|||0000-0003-1159-4636
  • Ventura, Salvador|||0000-0002-9652-6351
The aggregation of transthyretin (TTR) results in life-threatening transthyretin amyloidosis. Familial forms of the disease arise from point mutations that destabilize the TTR tetramer, leading to its dissociation and/or monomer unfolding and subsequent formation of amyloid fibrils. Small molecules that kinetically stabilize the native tetramer effectively inhibit this aggregation. Although over 300 X-ray crystal structures of TTR have been determined, these data refer to a static structure and do not capture the conformational effects of mutations and ligand binding. Here, we demonstrate that hydrogen-deuterium exchange (HDX) and fast photochemical oxidation of proteins (FPOP) coupled with mass spectrometry (MS) offer critical insights into the conformational dynamics associated with TTR amyloidogenic mutations and the binding of kinetic stabilizers. The results indicate that the design of TTR binders should consider the specific conformational traits of each TTR pathogenic variant. We propose that incorporating MS-based techniques into TTR drug discovery will expedite the development of effective pathology-specific aggregation inhibitors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

AGGRESCAN and its evolution, A two-decade perspective on protein aggregation prediction

  • Pesce, Giulia|||0000-0002-3979-6072
  • Solé Pozas, Josep Oriol|||0009-0008-0005-6174
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is a widespread phenomenon with profound biological, biomedical, and biotechnological implications. In human disease, aberrant protein self-assembly is a hallmark of numerous neurodegenerative disorders, whereas in the biopharmaceutical industry, aggregation complicates the production, stability, and formulation of therapeutic proteins. The Aggrescan platform was one of the first empirically based tools designed to predict aggregation-prone regions (APRs) within protein sequences. It has since expanded to incorporate three-dimensional structural contexts and environmental conditions. This review provides a comprehensive overview of the development, application, and impact of the Aggrescan family of tools, which includes AGGRESCAN, Aggrescan3D, and the recent Aggrescan4D. We examine the algorithmic foundations, empirical validation, and key use cases spanning fields from biotechnology to biomedical research. Additionally, we describe how the recent integration of AlphaFold models has enabled proteome-scale exploration of aggregation determinants. This review highlights how Aggrescan has evolved alongside with advances in the field, becoming a reliable and accessible tool for studying and redesigning protein aggregation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive protein datasets and benchmarking for liquid-liquid phase separation studies

  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Arribas-Ruiz, Eva
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Ventura, Salvador|||0000-0002-9652-6351
Proteins self-organize in dynamic cellular environments by assembling into reversible biomolecular condensates through liquid-liquid phase separation (LLPS). These condensates can comprise single or multiple proteins, with different roles in the ensemble's structural and functional integrity. Driver proteins form condensates autonomously, while client proteins just localize within them. Although several databases exist to catalog proteins undergoing LLPS, they often contain divergent data that impedes interoperability between these resources. Additionally, there is a lack of consensus on selecting proteins without explicit experimental association with condensates under physiological conditions (non-LLPS proteins or negative proteins). These two aspects have prevented the generation of reliable predictive models and fair benchmarks. In this work, we use an integrated biocuration protocol to analyze information from all relevant LLPS databases and generate confident datasets of client and driver proteins. We introduce standardized negative datasets, encompassing both globular and disordered proteins. To validate our datasets, we investigate specific physicochemical traits related to LLPS across different subsets of protein sequences and benchmark them against 16 predictive algorithms. We observe significant differences not only between positive and negative instances but also among LLPS proteins themselves. The datasets from this study are available as a website at and as a data repository at . Our datasets offer a reliable means for confidently assessing the specific roles of proteins in LLPS and identifying key differences in physicochemical properties underlying this process. Moreover, we describe limitations in classical and state-of-the-art predictive algorithms by providing the most comprehensive benchmark to date. {'@id': 'Par4', 'graphic': {'@position': 'anchor', '@id': 'MO1', '@orientation': 'portrait', '@xlink:href': '13059_2025_3668_Figa_HTML.jpg'}} The online version contains supplementary material available at 10.1186/s13059-025-03668-6.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Targetable N-Terminal Motif Orchestrates α-Synuclein Oligomer-to-Fibril Conversion

  • Santos, Jaime
  • Cuéllar, Jorge
  • Pallarès, Irantzu
  • Byrd, Emily J
  • Lends, Alons
  • Moro, Fernando
  • Abdul-Shukkoor, Muhammed Bilal
  • López-Pujol, Jordi
  • Velasco-Carneros, Lorea
  • Sobott, Frank
  • Otzen, Daniel E
  • Calabrese, Antonio N
  • Muga, Arturo
  • Pedersen, Jan Skov
  • Loquet, Antoine
  • Valpuesta, José M.
  • Radford, Sheena E
  • Ventura, Salvador
Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson's disease. However, the development of oligomer-targeting therapeutics is constrained by our limited knowledge of their structure and the molecular determinants driving their conversion to fibrils. Phenol-soluble modulin α3 (PSMα3) is a nanomolar peptide binder of α-synuclein oligomers that inhibits aggregation by blocking oligomer-to-fibril conversion. Here, we investigate the binding of PSMα3 to α-synuclein oligomers to discover the mechanistic basis of this protective activity. We find that PSMα3 selectively targets an α-synuclein N-terminal motif (residues 36-61) that populates a distinct conformation in the mono- and oligomeric states. This α-synuclein region plays a pivotal role in oligomer-to-fibril conversion as its absence renders the central NAC domain insufficient to prompt this structural transition. The hereditary mutation G51D, associated with early onset Parkinson's disease, causes a conformational fluctuation in this region, leading to delayed oligomer-to-fibril conversion and an accumulation of oligomers that are resistant to remodeling by molecular chaperones. Overall, our findings unveil a new targetable region in α-synuclein oligomers, advance our comprehension of oligomer-to-amyloid fibril conversion, and reveal a new facet of α-synuclein pathogenic mutations., The Spanish Ministry of Economy and Competitiveness (MINECO) grant BIO2017-91475-EXP (SV), the Spanish Ministry of Science and Innovation (MICINN) grants PID2019-105017RB-I00 (SV) and PID2022-137963OB-I00 (SV and IP), the MICINN grant PID2019-105872 GB-I00 (JMV) and PID2022-137175NB-I00 (JMV and JC), the MICINN grant PID2019-111068GB-I00 (AM) ICREA-Aca- demia 2015 (SV), the MICINN doctoral grant FPU17/01157 (JS), the Early postdoc mobility project SNSF P2EZP2_184258 (AL), the Basque Government grant IT1745-22 (FM), the BBSRC BB/M011151/1 grant (EJB), the Sir Henry Dale Fellowship jointly funded by Wellcome and the Royal Society 220628/Z/20/Z (ANC), the Royal Society grant RGS\R2\222357 (ANC), the University Academic Fellowship from the University of Leeds (ANC), and the Royal Society Research Professorship RSRP/R1/211057 (SER) are the funding sources., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations

  • Pinheiro, Francisca
  • Kant, Ravi
  • Chemuru, Saketh
  • Varejão, Nathalia
  • Velázquez-Campoy, Adrián
  • Reverter, David
  • Pallarès, Irantzu
  • Gross, Michael L.
  • Ventura, Salvador
The aggregation of transthyretin (TTR) results in life-threatening transthyretin amyloidosis. Familial forms of the disease arise from point mutations that destabilize the TTR tetramer, leading to its dissociation and/or monomer unfolding and subsequent formation of amyloid fibrils. Small molecules that kinetically stabilize the native tetramer effectively inhibit this aggregation. Although over 300 X-ray crystal structures of TTR have been determined, these data refer to a static structure and do not capture the conformational effects of mutations and ligand binding. Here, we demonstrate that hydrogen–deuterium exchange (HDX) and fast photochemical oxidation of proteins (FPOP) coupled with mass spectrometry (MS) offer critical insights into the conformational dynamics associated with TTR amyloidogenic mutations and the binding of kinetic stabilizers. The results indicate that the design of TTR binders should consider the specific conformational traits of each TTR pathogenic variant. We propose that incorporating MS-based techniques into TTR drug discovery will expedite the development of effective pathology-specific aggregation inhibitors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targetable N-Terminal Motif Orchestrates α-Synuclein Oligomer-to-Fibril Conversion

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Cuéllar, Jorge|||0000-0002-7789-807X
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Byrd, Emily|||0000-0002-9876-1400
  • Lends, Alons
  • Moro, Fernando
  • Abdul-Shukkoor, Muhammed Bilal
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Velasco-Carneros, Lorea|||0000-0002-1296-9498
  • Sobott, Frank|||0000-0001-9029-1865
  • Otzen, Daniel E.|||0000-0002-2918-8989
  • Calabrese, Antonio N.|||0000-0003-2437-7761
  • Muga, Arturo|||0000-0003-0345-6882
  • Pedersen, Jan Skov|||0000-0002-7768-0206
  • Loquet, Antoine|||0000-0001-7176-7813
  • Valpuesta, Jose María|||0000-0001-7468-8053
  • Radford, Sheena E.|||0000-0002-3079-8039
  • Ventura, Salvador|||0000-0002-9652-6351
Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson's disease. However, the development of oligomer-targeting therapeutics is constrained by our limited knowledge of their structure and the molecular determinants driving their conversion to fibrils. Phenol-soluble modulin α3 (PSMα3) is a nanomolar peptide binder of α-synuclein oligomers that inhibits aggregation by blocking oligomer-to-fibril conversion. Here, we investigate the binding of PSMα3 to α-synuclein oligomers to discover the mechanistic basis of this protective activity. We find that PSMα3 selectively targets an α-synuclein N-terminal motif (residues 36-61) that populates a distinct conformation in the mono- and oligomeric states. This α-synuclein region plays a pivotal role in oligomer-to-fibril conversion as its absence renders the central NAC domain insufficient to prompt this structural transition. The hereditary mutation G51D, associated with early onset Parkinson's disease, causes a conformational fluctuation in this region, leading to delayed oligomer-to-fibril conversion and an accumulation of oligomers that are resistant to remodeling by molecular chaperones. Overall, our findings unveil a new targetable region in α-synuclein oligomers, advance our comprehension of oligomer-to-amyloid fibril conversion, and reveal a new facet of α-synuclein pathogenic mutations.